Riya Baibhawi

Loneliness Epidemic. Seoul Is Spending $327 Million To Stop It

Loneliness

<span>South Korea</span> is grappling with a growing emotional pandemic: <span>loneliness</span>. As young people withdraw from society, choosing isolation over connection, the phenomenon known as hikikomori, a Japanese term referring to reclusive individuals, has gained alarming prevalence. In 2022, it was estimated that up to 244,000 South Koreans had withdrawn from the world, spending their lives locked inside their rooms for months at a time.

This withdrawal from social life has stark consequences. The number of "lonely deaths" has also surged, reaching 3,661 last year, up from 3,559 in 2022, and 3,378 in 2021, according to data from the Ministry of Health and Welfare. These figures reflect a sobering reality as an increasing number of South Koreans are dying alone, often unnoticed for extended periods.

Part of the rise in lonely deaths can be attributed to the ministry’s broader definition. In the past, only deaths where bodies were discovered after a significant delay were counted. Now, anyone who dies in social isolation—cut off from family or friends, whether from suicide or illness—is included in the category. This shift highlights the growing crisis of isolation, particularly among middle-aged and elderly men. More than 84% of lonely deaths in 2023 were male, with men in their 50s and 60s accounting for more than half of the total.

South <span>Korea</span>’s demographic trends are further exacerbating the issue. With an aging population and declining birth rates, deaths have consistently outpaced births in recent years, contributing to the overall rise in lonely deaths. Yet, beyond the numbers lies a deeper cultural issue: the struggle with loneliness, which is experienced differently in South Korea compared to other countries.

While loneliness is a universal feeling, it manifests uniquely in South Korea. According to psychology professor An, “Koreans may not necessarily feel lonelier than others, but the reasons behind their loneliness differ.” In many cultures, loneliness stems from unfulfilled relationships, but in South Korea, people often associate loneliness with a lack of purpose or a sense of inadequacy. Many Millennials and Gen Z Koreans are deeply self-critical, afraid of failure, and sensitive to societal expectations.

A 2023 study highlighted that loneliness in Korea is shaped by cultural nuances. Korean society emphasizes relational orientation, meaning people often define themselves in relation to others. As a result, even those with active social lives may feel profound loneliness if they perceive themselves as not contributing meaningfully to society. The intense pressure to achieve, combined with rising single-person households, reduced social interactions, and the dominance of social media, fuels feelings of inadequacy.

“When everyone pursues the same values excessively, we end up losing ourselves,” An explained. “Our society demands highly collective social living but often fails to respect the individual,” leaving many struggling with isolation and failure. As South Korea continues to navigate this emotional crisis, addressing loneliness remains a complex challenge requiring cultural and structural shifts.

Health Conditions A-Z

health

south korea

korea

Loneliness pandemic

Mental Health

What Is The Viral Cortisol Cocktail? Does It Really Work?

New Texas Law Could Change Labeling Of Food Additives Across US

Measles Outbreak: North Carolina Confirms Its First Case Of 2025

Health News

High-Protein No Cook Dishes You Should Try

Yoga Poses That Aid In Digestion

Low Calorie Dinner Options For Weight Loss

Cardiac Arrest Vs. Heart Attack: Difference Explained Under 60 Seconds

High Protein Low-Carb Snacks To Have On The Go

Knee Exercises Desk Workers Should Do For Joint Health

Why Do I Feel Sleepy During The Day?

High Protein Early Morning Meals To Keep You Full Till Lunch

International Yoga Day 2025: Benefits of Doing Tadasana Every Morning

High-Carb Foods That Are Really Healthy

Dementia Vs Alzheimer’s: Difference Explained Under 60 Seconds

Healthy Staple Foods To Make Eating Healthy Easier

Are You Dealing With Abandonment Issues? Signs And Risk Factors

Mid-Work Healthy Snacks You Can Eat Throughout The Day

Common Mistakes You May Be Making In The Gym

Strengthen Your Legs Muscles With These Exercises

Beat Anxiety With Books: How Reading Helps With Stress

Ghee For Health: Ayurvedic Health Benefits Of Clarified Butter

Common Mistakes You Are Making While Walking

Exercises You Should Do At Home When You Skip Gym

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Ways To Ease Nighttime Anxiety

Smoothie Ideas That Can Help With Weight Loss

Low Fat Foods That Are Actually Unhealthy

All Suryanamaskar Poses And How To Do Them

Do Changing Seasons Affect Your Weight?

Can Heatwave Affect Your Diet?

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

South Korea is grappling with a growing emotional pandemic: loneliness. As young people withdraw from society, choosing isolation over connection, the phenomenon known as hikikomori, a Japanese term referring to reclusive individuals, has gained alarming prevalence. In 2022, it was estimated that up to 244,000 South Koreans had withdrawn from the world, spending their lives locked inside their rooms for months at a time.This withdrawal from social life has stark consequences. The number of "lonely deaths" has also surged, reaching 3,661 last year, up from 3,559 in 2022, and 3,378 in 2021, according to data from the Ministry of Health and Welfare. These figures reflect a sobering reality as an increasing number of South Koreans are dying alone, often unnoticed for extended periods.Part of the rise in lonely deaths can be attributed to the ministry’s broader definition. In the past, only deaths where bodies were discovered after a significant delay were counted. Now, anyone who dies in social isolation—cut off from family or friends, whether from suicide or illness—is included in the category. This shift highlights the growing crisis of isolation, particularly among middle-aged and elderly men. More than 84% of lonely deaths in 2023 were male, with men in their 50s and 60s accounting for more than half of the total.South Korea’s demographic trends are further exacerbating the issue. With an aging population and declining birth rates, deaths have consistently outpaced births in recent years, contributing to the overall rise in lonely deaths. Yet, beyond the numbers lies a deeper cultural issue: the struggle with loneliness, which is experienced differently in South Korea compared to other countries.While loneliness is a universal feeling, it manifests uniquely in South Korea. According to psychology professor An, “Koreans may not necessarily feel lonelier than others, but the reasons behind their loneliness differ.” In many cultures, loneliness stems from unfulfilled relationships, but in South Korea, people often associate loneliness with a lack of purpose or a sense of inadequacy. Many Millennials and Gen Z Koreans are deeply self-critical, afraid of failure, and sensitive to societal expectations.A 2023 study highlighted that loneliness in Korea is shaped by cultural nuances. Korean society emphasizes relational orientation, meaning people often define themselves in relation to others. As a result, even those with active social lives may feel profound loneliness if they perceive themselves as not contributing meaningfully to society. The intense pressure to achieve, combined with rising single-person households, reduced social interactions, and the dominance of social media, fuels feelings of inadequacy.“When everyone pursues the same values excessively, we end up losing ourselves,” An explained. “Our society demands highly collective social living but often fails to respect the individual,” leaving many struggling with isolation and failure. As South Korea continues to navigate this emotional crisis, addressing loneliness remains a complex challenge requiring cultural and structural shifts.

Loneliness Epidemic. Seoul Is Spending 327 Million To Stop It

loneliness epidemic. seoul is spending $327 million to stop it

Health and Me

Ishita Roy

10 Worst US Cities To Live In During Seasonal Allergies

10 worst us cities to live in during seasonal allergies

These Are The Unusual Symptoms Of The Newly Identified COVID-19 Variant NB.1.8.1

these are the unusual symptoms of the newly identified covid-19 variant nb.1.8.1

Former Anti-Vaccine Leader to Weigh In On CDC Vaccine Strategy

former anti-vaccine leader to weigh in on cdc vaccine strategy

Health & Wellness

Nearly 30 People in England Get Rare Illness After Botox; How Safe Are Cosmetic Procedures, Really?

nearly 30 people in england get rare illness after botox; how safe are cosmetic procedures, really?

Amid the ongoing <span>measles</span> outbreak in the United States, the state of North Carolina has confirmed its first case in 2025. The North Carolina Department of Health and Human Services (NCDHHS) confirmed a case of measles in a child who was visiting Forsyth County and Guilford County. 

The child became ill while traveling to North Carolina from a region where measles had already been reported. The news is confirmed as per the NCDHHS release. 

The authorities are now also asking people who have visited the below mentioned location to review their immunization records or contact a healthcare provider to ensure that you are updated with the measles-mumps-rubella vaccine. 

<ul><li>PTI Airport in Greensboro</li><li>Sleep Inn, 1406 Heartland Dr., Kernersville</li><li>McDonalds, 14000 Heartland Dr., Kernersville</li><li>Greensboro Science Center, 4301 Lawndale Dr., Greensboro</li><li>Ice cream shop at Piedmont Triad Farmers Market, Greensboro</li><li>Greensboro Aquatic Center Foyer, 1921 W. Gate City Blvd., Greensboro</li><li>Greensboro Partee Shack, 3712 S. Holden Rd., Greensboro</li><li>Lowes Foods, 240 Market View Dr., Kernersville</li></ul>

The NCDHHS has also recommended that anyone unvaccinated and older than one year must get the measles vaccination. 

However, when it comes to lab tests, the NCDHHS recommends that it is not necessary for people who were exposed, unless they develop symptoms of measles, including fever and rash. These symptoms can start from 7 to 21 days of getting infected. “Getting vaccinated against measles continues to be the most important step we can take to protect ourselves and our loved ones,” NCDHHS Secretary Dev Sangvai said. “It is important to check with your health care provider to ensure you are current with all your vaccines.” 

As per the Centers for Disease Control and Prevention (CDC), measles is a highly contagious disease that comes with rashes and are especially prone to kids under the age of 5. 

If one person gets it then 9 out of 10 people around the infected person may become infected.

Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. It can affect people of all ages, despite being considered primarily a childhood illness. 

Measles is marked by prodromal fever, cough, coryza, conjunctivitis, and pathognomonic enanthem (ie, Koplik spots), followed by an erythematous maculopapular rash on the third to seventh day. 

The World Health Organization (WHO), calls measles as one of the world's most contagious disease, which is spread by contact with infected nasal or throat secretions through coughing or sneezing, or breathing the air that was breathed by someone with measles. The virus remains active and contagious in the air or on infected surfaces for up to two hours. 

WHO notes that any non-immune person (not vaccinated or vaccinated but did not develop immunity) can become infected. Unvaccinated young children and pregnant persons are at highest risk of severe measles complications.

measles

north carolina first measles case

health news

health news us

us health news

Amid the ongoing measles outbreak in the United States, the state of North Carolina has confirmed its first case in 2025. The North Carolina Department of Health and Human Services (NCDHHS) confirmed a case of measles in a child who was visiting Forsyth County and Guilford County. How Did The Child Fall Sick?The child became ill while traveling to North Carolina from a region where measles had already been reported. The news is confirmed as per the NCDHHS release. The authorities are now also asking people who have visited the below mentioned location to review their immunization records or contact a healthcare provider to ensure that you are updated with the measles-mumps-rubella vaccine. The Locations Are:PTI Airport in GreensboroSleep Inn, 1406 Heartland Dr., KernersvilleMcDonalds, 14000 Heartland Dr., KernersvilleGreensboro Science Center, 4301 Lawndale Dr., GreensboroIce cream shop at Piedmont Triad Farmers Market, GreensboroGreensboro Aquatic Center Foyer, 1921 W. Gate City Blvd., GreensboroGreensboro Partee Shack, 3712 S. Holden Rd., GreensboroLowes Foods, 240 Market View Dr., KernersvilleWhat Are The safety Guidelines?The NCDHHS has also recommended that anyone unvaccinated and older than one year must get the measles vaccination. However, when it comes to lab tests, the NCDHHS recommends that it is not necessary for people who were exposed, unless they develop symptoms of measles, including fever and rash. These symptoms can start from 7 to 21 days of getting infected. “Getting vaccinated against measles continues to be the most important step we can take to protect ourselves and our loved ones,” NCDHHS Secretary Dev Sangvai said. “It is important to check with your health care provider to ensure you are current with all your vaccines.” What Is Measles?As per the Centers for Disease Control and Prevention (CDC), measles is a highly contagious disease that comes with rashes and are especially prone to kids under the age of 5. If one person gets it then 9 out of 10 people around the infected person may become infected.Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. It can affect people of all ages, despite being considered primarily a childhood illness. Measles is marked by prodromal fever, cough, coryza, conjunctivitis, and pathognomonic enanthem (ie, Koplik spots), followed by an erythematous maculopapular rash on the third to seventh day. Who Is At Risk?The World Health Organization (WHO), calls measles as one of the world's most contagious disease, which is spread by contact with infected nasal or throat secretions through coughing or sneezing, or breathing the air that was breathed by someone with measles. The virus remains active and contagious in the air or on infected surfaces for up to two hours. WHO notes that any non-immune person (not vaccinated or vaccinated but did not develop immunity) can become infected. Unvaccinated young children and pregnant persons are at highest risk of severe measles complications.

measles outbreak: north carolina confirms its first case of 2025

Tanya Dutt

Not Wegovy or Mounjaro Or Ozempic: This New Monthly Weight Loss Jab Helped People Drop 20% Body Fat

Wegovy vs. Mounjaro: Which Weight-Loss Jab Works Best?

wegovy vs. mounjaro: which weight-loss jab works best?

Novo Nordisk Launches Bestseller Weight Loss Drug Wegovy In India

novo nordisk launches bestseller weight loss drug wegovy in india

Mounjaro For Weight Loss: How It Works, Duration, Side Effects, Cost And More

mounjaro for weight loss: how it works, duration, side effects, cost and more

Nutrition

Feast, Famine And Fat Loss: New Diet Trend 'Better Than Intermittent Fasting' Could Help You Lose Weight Faster

feast, famine and fat loss: new diet trend 'better than intermittent fasting' could help you lose weight faster

A new clinical trial has uncovered the breakthrough promise of a <span>new weight loss medication</span>, MariTide, that can be taken only once monthly. Amgen developed the investigational drug, and it has demonstrated remarkable weight loss outcomes up to 20% in individuals with obesity. The Phase 2 trial results, which were released in The New England Journal of Medicine and presented at the American Diabetes Association's annual meeting 2025, may be a turning point in the treatment of obesity and Type 2 diabetes worldwide.

MariTide is a GLP-1 receptor agonist, a type of drug whose behavior is well-known to reduce weight and control Type 2 diabetes. It differentiates from current competitors like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, because it has a distinct molecular structure. MariTide contains a monoclonal antibody that means the drug can remain in the body longer. This capability makes the drug possible to give as a once-monthly injection, a major improvement over its weekly-injected counterparts.

Amgen's Phase 2 clinical trial consisted of almost 600 adults, divided into two groups: one with obesity alone and the other with obesity and Type 2 diabetes. Volunteers were assigned to take one of three dose levels of MariTide or a dummy shot. They took monthly injections for 52 weeks, and some in the obesity group started with a low dose that was increased incrementally.

The findings from the Phase 2 clinical trial of MariTide were nothing short of remarkable. Participants who had obesity but did not have diabetes experienced an average weight loss of up to 20% of their body weight after 52 weeks of treatment. Meanwhile, those who were managing both obesity and Type 2 diabetes saw an average weight loss of up to 17%. In sharp contrast, patients in the placebo groups showed only slight decreases in body weight, 2.6% for the group with obesity alone and only 1.4% for the group with obesity and diabetes. These findings highlight the great potential of MariTide as a very effective, once-a-month weight loss treatment.

These findings place MariTide on par with Wegovy and Zepbound in weight loss effects. Although Wegovy studies recorded a 15% decrease after 68 weeks and Zepbound delivered a 22.5% decrease after 72 weeks, MariTide's monthly regimen and similar effectiveness make it a strong contender.

<h2>Health Benefits of Using MariTide</h2>

MariTide is not only gaining recognition for its effectiveness at weight loss—it's also emerging as a full-range cardiometabolic therapy. Based on trial results, patients on MariTide experienced a dramatic decrease in A1c values, a key measure of long-term blood glucose control. For patients with diabetes, the medication reduced A1c by as much as 2.2 percentage points, outpacing expected decreases of 1.5 to 2.0 points with established GLP-1 therapies such as Ozempic and Mounjaro. But the advantages didn't end there. The research also observed significant reductions in blood pressure, cholesterol, and markers of inflammation, pointing to the potential of MariTide beyond the scale. These results indicate that the drug may provide an all-around solution to obesity as well as other chronic diseases such as cardiovascular disease and type 2 diabetes, making it an attractive option in the changing scenario of metabolic health treatments.

Similar to other GLP-1 receptor agonists, MariTide has a similar action to glucagon-like peptide-1, a hormone that controls blood glucose and hunger. It increases the release of insulin, decreases the release of glucagon, and retards gastric emptying. MariTide differs from other drugs in that it contains a monoclonal antibody that keeps the drug in the body longer. Monthly dosing is made possible by this advance, and treatment compliance may be enhanced by less frequent injections.

<h2>Side Effects of 'MariTide' That People Need to Know</h2>

Similar to other GLP-1 drugs, side effects in the gastrointestinal tract were most frequently reported during the trial. These consisted of:

<ul><li>Nausea</li><li>Vomiting</li><li>Diarrhea</li><li>Abdominal discomfort</li></ul>

The side effect profile was comparable to other drugs in the same class according to the research team and largely tolerable overall. Large-scale Phase 3 trials will be important to best evaluate long-term safety and infrequent adverse events, though.

<h2><span rel="noindex">MariTide vs Wegovy</span>, Mounjaro, and Others</h2>

If approved, MariTide would represent Amgen's foray into a weight loss market led by Novo Nordisk and Eli Lilly. Wegovy and Mounjaro have experienced explosive growth as a result of their robust efficacy results. Yet, MariTide's monthly dosing regimen and dual utility in diabetes care and weight loss may resonate with a vast patient population.

The comparisons between MariTide and existing GLP-1 drugs have not yet been conducted. Still, the early data suggests that Amgen’s candidate could stand toe-to-toe with the industry giants.

Amgen said it plans a Phase 3 clinical trial to further study MariTide for 72 weeks. If all goes well, the results of this research may lead to FDA approval and future distribution worldwide. Most analysts expect it will be at least a couple of years before MariTide is widely available, though.

With rates of obesity on the rise globally and related health issues costing billions each year, effective, affordable, and sustainable weight-loss solutions have never been more vital. MariTide's encouraging results provide a timely new alternative to an expanding stockpile of obesity-fighting weapons.

weight loss injection

maritide weight loss drug

monthly obesity injection

amgen weight loss trial

glp 1 weight loss drugs

maritide vs wegovy

new weight loss medication

fda obesity treatment

A new clinical trial has uncovered the breakthrough promise of a new weight loss medication, MariTide, that can be taken only once monthly. Amgen developed the investigational drug, and it has demonstrated remarkable weight loss outcomes up to 20% in individuals with obesity. The Phase 2 trial results, which were released in The New England Journal of Medicine and presented at the American Diabetes Association's annual meeting 2025, may be a turning point in the treatment of obesity and Type 2 diabetes worldwide.MariTide is a GLP-1 receptor agonist, a type of drug whose behavior is well-known to reduce weight and control Type 2 diabetes. It differentiates from current competitors like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, because it has a distinct molecular structure. MariTide contains a monoclonal antibody that means the drug can remain in the body longer. This capability makes the drug possible to give as a once-monthly injection, a major improvement over its weekly-injected counterparts.Amgen's Phase 2 clinical trial consisted of almost 600 adults, divided into two groups: one with obesity alone and the other with obesity and Type 2 diabetes. Volunteers were assigned to take one of three dose levels of MariTide or a dummy shot. They took monthly injections for 52 weeks, and some in the obesity group started with a low dose that was increased incrementally.The findings from the Phase 2 clinical trial of MariTide were nothing short of remarkable. Participants who had obesity but did not have diabetes experienced an average weight loss of up to 20% of their body weight after 52 weeks of treatment. Meanwhile, those who were managing both obesity and Type 2 diabetes saw an average weight loss of up to 17%. In sharp contrast, patients in the placebo groups showed only slight decreases in body weight, 2.6% for the group with obesity alone and only 1.4% for the group with obesity and diabetes. These findings highlight the great potential of MariTide as a very effective, once-a-month weight loss treatment.These findings place MariTide on par with Wegovy and Zepbound in weight loss effects. Although Wegovy studies recorded a 15% decrease after 68 weeks and Zepbound delivered a 22.5% decrease after 72 weeks, MariTide's monthly regimen and similar effectiveness make it a strong contender.Health Benefits of Using MariTideMariTide is not only gaining recognition for its effectiveness at weight loss—it's also emerging as a full-range cardiometabolic therapy. Based on trial results, patients on MariTide experienced a dramatic decrease in A1c values, a key measure of long-term blood glucose control. For patients with diabetes, the medication reduced A1c by as much as 2.2 percentage points, outpacing expected decreases of 1.5 to 2.0 points with established GLP-1 therapies such as Ozempic and Mounjaro. But the advantages didn't end there. The research also observed significant reductions in blood pressure, cholesterol, and markers of inflammation, pointing to the potential of MariTide beyond the scale. These results indicate that the drug may provide an all-around solution to obesity as well as other chronic diseases such as cardiovascular disease and type 2 diabetes, making it an attractive option in the changing scenario of metabolic health treatments.How MariTide Works?Similar to other GLP-1 receptor agonists, MariTide has a similar action to glucagon-like peptide-1, a hormone that controls blood glucose and hunger. It increases the release of insulin, decreases the release of glucagon, and retards gastric emptying. MariTide differs from other drugs in that it contains a monoclonal antibody that keeps the drug in the body longer. Monthly dosing is made possible by this advance, and treatment compliance may be enhanced by less frequent injections.Side Effects of 'MariTide' That People Need to KnowSimilar to other GLP-1 drugs, side effects in the gastrointestinal tract were most frequently reported during the trial. These consisted of:NauseaVomitingDiarrheaAbdominal discomfortThe side effect profile was comparable to other drugs in the same class according to the research team and largely tolerable overall. Large-scale Phase 3 trials will be important to best evaluate long-term safety and infrequent adverse events, though.MariTide vs Wegovy, Mounjaro, and OthersIf approved, MariTide would represent Amgen's foray into a weight loss market led by Novo Nordisk and Eli Lilly. Wegovy and Mounjaro have experienced explosive growth as a result of their robust efficacy results. Yet, MariTide's monthly dosing regimen and dual utility in diabetes care and weight loss may resonate with a vast patient population.The comparisons between MariTide and existing GLP-1 drugs have not yet been conducted. Still, the early data suggests that Amgen’s candidate could stand toe-to-toe with the industry giants.What’s Next for MariTide?Amgen said it plans a Phase 3 clinical trial to further study MariTide for 72 weeks. If all goes well, the results of this research may lead to FDA approval and future distribution worldwide. Most analysts expect it will be at least a couple of years before MariTide is widely available, though.With rates of obesity on the rise globally and related health issues costing billions each year, effective, affordable, and sustainable weight-loss solutions have never been more vital. MariTide's encouraging results provide a timely new alternative to an expanding stockpile of obesity-fighting weapons.

not wegovy or mounjaro or ozempic: this new monthly weight loss jab helped people drop 20% body fat

Global pharma giant Novo Nordisk launched its blockbuster weight loss drug <span>Wegovy</span> in India, a pivotal moment in the battle against increasing obesity levels in the nation. This follows closely on the heels of Eli Lilly's Mounjaro launch in India.

Wegovy, the semaglutide-based GLP-1 receptor agonist, will be available by the end of the month across major pharmacy chains in India. The once-weekly injectable prescription drug has already changed the landscape of obesity management in the United States and Europe.

"One out of every three patients attain 20% weight loss using the increased dose of Wegovy," stated Vikrant Shrotriya, Managing Director, Novo Nordisk India. The firm has completed late-stage trials involving 3,500 people in India, indicating encouraging results in sustained weight loss.

Wegovy will come in several dosages, ranging from Rs 4,336 for 0.25 mg to Rs 26,015 for the highest 2.4 mg dose. Its price is comparable to its rival Mounjaro, which was also launched in India last month in March.

Wegovy is timely given the increasing weight problem in India. A recent National Family Health Survey reveals that 24% of Indian women and 23% of Indian men aged between 15 and 49 years are overweight or obese—a notable increase from past years. India, with a population of over 1.4 billion and fast-emerging lifestyle diseases, is a huge market for weight-loss medications.

The medication has already proven to be successful across the world. Clinical trials have indicated that Wegovy consumers would lose around 15% of their body weight on average, especially when combined with a balanced diet and regular exercise. For comparison, Mounjaro (tirzepatide), being a dual GIP and GLP-1 agonist, experienced close to 23% of weight loss under the same circumstances.

Novo Nordisk's launch in India is at a time of corporate leadership transition, following the recent resignation of CEO Lars Fruergaard Jorgensen. The move is said by analysts to be intended to protect market share in a competitive environment rising from Lilly competition as well as Indian generic drugmakers who are gearing up to move into the field of obesity drugs when semaglutide's patent is about to end in 2026.

Although Wegovy brings new hope to millions of people with obesity, there are warnings with the medication. The drug has a boxed FDA warning about the potential for thyroid cancer, as suggested by studies on animals. Because of this, the drug is not approved for use in someone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

As India joins the global fight against obesity with cutting-edge therapies, India is all set to benefit from Novo Nordisk's Wegovy, which is ready to provide a new, science-driven solution for long-term weight management. The competition has already turned hot, and for Indian consumers, it could mean more options, improved results, and a new age of obesity treatment.

wegovy

wegovy india launch

obesity drug wegovy

semaglutide injection

weight loss medication india

novo nordisk wegovy

wegovy vs mounjaro

glp-1 weight loss drugs

Global pharma giant Novo Nordisk launched its blockbuster weight loss drug Wegovy in India, a pivotal moment in the battle against increasing obesity levels in the nation. This follows closely on the heels of Eli Lilly's Mounjaro launch in India.Wegovy, the semaglutide-based GLP-1 receptor agonist, will be available by the end of the month across major pharmacy chains in India. The once-weekly injectable prescription drug has already changed the landscape of obesity management in the United States and Europe."One out of every three patients attain 20% weight loss using the increased dose of Wegovy," stated Vikrant Shrotriya, Managing Director, Novo Nordisk India. The firm has completed late-stage trials involving 3,500 people in India, indicating encouraging results in sustained weight loss.Wegovy will come in several dosages, ranging from Rs 4,336 for 0.25 mg to Rs 26,015 for the highest 2.4 mg dose. Its price is comparable to its rival Mounjaro, which was also launched in India last month in March.Wegovy is timely given the increasing weight problem in India. A recent National Family Health Survey reveals that 24% of Indian women and 23% of Indian men aged between 15 and 49 years are overweight or obese—a notable increase from past years. India, with a population of over 1.4 billion and fast-emerging lifestyle diseases, is a huge market for weight-loss medications.The medication has already proven to be successful across the world. Clinical trials have indicated that Wegovy consumers would lose around 15% of their body weight on average, especially when combined with a balanced diet and regular exercise. For comparison, Mounjaro (tirzepatide), being a dual GIP and GLP-1 agonist, experienced close to 23% of weight loss under the same circumstances.Novo Nordisk's launch in India is at a time of corporate leadership transition, following the recent resignation of CEO Lars Fruergaard Jorgensen. The move is said by analysts to be intended to protect market share in a competitive environment rising from Lilly competition as well as Indian generic drugmakers who are gearing up to move into the field of obesity drugs when semaglutide's patent is about to end in 2026.Although Wegovy brings new hope to millions of people with obesity, there are warnings with the medication. The drug has a boxed FDA warning about the potential for thyroid cancer, as suggested by studies on animals. Because of this, the drug is not approved for use in someone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).As India joins the global fight against obesity with cutting-edge therapies, India is all set to benefit from Novo Nordisk's Wegovy, which is ready to provide a new, science-driven solution for long-term weight management. The competition has already turned hot, and for Indian consumers, it could mean more options, improved results, and a new age of obesity treatment.

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Loneliness Epidemic. Seoul Is Spending 327 Million To Stop It

Quick Stories

Measles Outbreak: North Carolina Confirms Its First Case Of 2025

Not Wegovy or Mounjaro Or Ozempic: This New Monthly Weight Loss Jab Helped People Drop 20% Body Fat

Novo Nordisk Launches Bestseller Weight Loss Drug Wegovy In India

Health Conditions A-Z

What Is The Viral Cortisol Cocktail? Does It Really Work?

New Texas Law Could Change Labeling Of Food Additives Across US

Measles Outbreak: North Carolina Confirms Its First Case Of 2025